Serum lipoprotein(a) in relation to ischemic heart disease and associated risk factors

Lipoprotein(a) (Lp(a)) consists of an LDL-like particle and the specific protein apo(a), which is very similar to plasminogen. Apo(a) contains repeated kringle structures and a serine protease domain, which cannot be activated by t-PA. Lp(a) is considered to be a predictor for atherosclerotic diseas...

Full description

Bibliographic Details
Main Author: Slunga, Lisbeth
Format: Doctoral Thesis
Language:English
Published: Umeå universitet, Klinisk kemi 1993
Subjects:
Online Access:http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-101298
http://nbn-resolving.de/urn:isbn:91-7174-828-8
id ndltd-UPSALLA1-oai-DiVA.org-umu-101298
record_format oai_dc
spelling ndltd-UPSALLA1-oai-DiVA.org-umu-1012982015-04-23T04:58:32ZSerum lipoprotein(a) in relation to ischemic heart disease and associated risk factorsengSlunga, LisbethUmeå universitet, Klinisk kemiUmeå universitet, MedicinUmeå : Umeå universitet1993Lipoprotein(a)lipidsepidemiologycoronary artery diseasecoronary angiographyHLA DRacute-phase proteinmyocardial infarctionHMG CoA reductase inhibitorsimvastatinLipoprotein(a) (Lp(a)) consists of an LDL-like particle and the specific protein apo(a), which is very similar to plasminogen. Apo(a) contains repeated kringle structures and a serine protease domain, which cannot be activated by t-PA. Lp(a) is considered to be a predictor for atherosclerotic disease. It has been found incorporated in atherosclerotic plaques and inhibits in vitro fibrinolysis. Lp(a) was determined in 1527 randomly selected individuals participating in the Northern Sweden WHO-MONICA project. A weak but significant relation between Lp(a) and increasing age was found. Menopausal status was the strongest independent predictor of Lp(a) level in women. Fibrinogen was independently related to Lp(a) in both sexes. Only a minor fraction of Lp(a) variance could be explained for in a multiple regression model, which is in agreement with the contention that Lp(a) is highly genetically determined. Lp(a) was determined in 1571 patients investigated with coronary angiography because of suspected severe coronary artery disease (CAD). Patients with proven CAD at elective angiography had significantly higher Lp(a) than patients without significant CAD or healthy controls. Lp(a) was found to be an independent discriminator of CAD in both sexes. HLA-DR genotype 13 or 17 was found more frequently in 30 male patients with angiographic CAD at young age (&lt; 50 years) than in 30 age matched controls. These genotypes were common in patients with high Lp(a) levels, which indicates that Lp(a) may be related to immunological processes. The reaction of Lp(a) was investigated in 32 patients with acute myocardial infarction (AMI). Lp(a) increased during the first week, but the response was comparatively weak. Individual Lp(a) responses were heterogeneous and no correlations to infarct size or changes in the acute phase proteins were found. In a randomized cross-over study on 36 hypercholesterolaemic patients treated with simvastatin/placebo during 12+12 weeks Lp(a) did not change significantly, but patients with high Lp(a) levels at baseline tended to develop further increased Lp(a). To conclude, Lp(a) was found to be an independent predictor of angiographic CAD in both men and women. Lp(a) levels are primarily genetically determined and only a small fraction of Lp(a) variance could be explained by other factors in this study. Lp(a) may be related to HLA DR types and immunological processes involved in atherosclerotic disease. Lp(a) increased slightly during the first week of AMI, but was not related to changes in the acute-phase proteins. The effective LDL-lowering agent simvastatin did not influence Lp(a) significantly. <p>Diss. (sammanfattning) Umeå : Umeå universitet, 1993, härtill 5 uppsatser.</p>digitalisering@umuDoctoral thesis, comprehensive summaryinfo:eu-repo/semantics/doctoralThesistexthttp://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-101298urn:isbn:91-7174-828-8Umeå University medical dissertations, 0346-6612 ; 386application/pdfinfo:eu-repo/semantics/openAccess
collection NDLTD
language English
format Doctoral Thesis
sources NDLTD
topic Lipoprotein(a)
lipids
epidemiology
coronary artery disease
coronary angiography
HLA DR
acute-phase protein
myocardial infarction
HMG CoA reductase inhibitor
simvastatin
spellingShingle Lipoprotein(a)
lipids
epidemiology
coronary artery disease
coronary angiography
HLA DR
acute-phase protein
myocardial infarction
HMG CoA reductase inhibitor
simvastatin
Slunga, Lisbeth
Serum lipoprotein(a) in relation to ischemic heart disease and associated risk factors
description Lipoprotein(a) (Lp(a)) consists of an LDL-like particle and the specific protein apo(a), which is very similar to plasminogen. Apo(a) contains repeated kringle structures and a serine protease domain, which cannot be activated by t-PA. Lp(a) is considered to be a predictor for atherosclerotic disease. It has been found incorporated in atherosclerotic plaques and inhibits in vitro fibrinolysis. Lp(a) was determined in 1527 randomly selected individuals participating in the Northern Sweden WHO-MONICA project. A weak but significant relation between Lp(a) and increasing age was found. Menopausal status was the strongest independent predictor of Lp(a) level in women. Fibrinogen was independently related to Lp(a) in both sexes. Only a minor fraction of Lp(a) variance could be explained for in a multiple regression model, which is in agreement with the contention that Lp(a) is highly genetically determined. Lp(a) was determined in 1571 patients investigated with coronary angiography because of suspected severe coronary artery disease (CAD). Patients with proven CAD at elective angiography had significantly higher Lp(a) than patients without significant CAD or healthy controls. Lp(a) was found to be an independent discriminator of CAD in both sexes. HLA-DR genotype 13 or 17 was found more frequently in 30 male patients with angiographic CAD at young age (&lt; 50 years) than in 30 age matched controls. These genotypes were common in patients with high Lp(a) levels, which indicates that Lp(a) may be related to immunological processes. The reaction of Lp(a) was investigated in 32 patients with acute myocardial infarction (AMI). Lp(a) increased during the first week, but the response was comparatively weak. Individual Lp(a) responses were heterogeneous and no correlations to infarct size or changes in the acute phase proteins were found. In a randomized cross-over study on 36 hypercholesterolaemic patients treated with simvastatin/placebo during 12+12 weeks Lp(a) did not change significantly, but patients with high Lp(a) levels at baseline tended to develop further increased Lp(a). To conclude, Lp(a) was found to be an independent predictor of angiographic CAD in both men and women. Lp(a) levels are primarily genetically determined and only a small fraction of Lp(a) variance could be explained by other factors in this study. Lp(a) may be related to HLA DR types and immunological processes involved in atherosclerotic disease. Lp(a) increased slightly during the first week of AMI, but was not related to changes in the acute-phase proteins. The effective LDL-lowering agent simvastatin did not influence Lp(a) significantly. === <p>Diss. (sammanfattning) Umeå : Umeå universitet, 1993, härtill 5 uppsatser.</p> === digitalisering@umu
author Slunga, Lisbeth
author_facet Slunga, Lisbeth
author_sort Slunga, Lisbeth
title Serum lipoprotein(a) in relation to ischemic heart disease and associated risk factors
title_short Serum lipoprotein(a) in relation to ischemic heart disease and associated risk factors
title_full Serum lipoprotein(a) in relation to ischemic heart disease and associated risk factors
title_fullStr Serum lipoprotein(a) in relation to ischemic heart disease and associated risk factors
title_full_unstemmed Serum lipoprotein(a) in relation to ischemic heart disease and associated risk factors
title_sort serum lipoprotein(a) in relation to ischemic heart disease and associated risk factors
publisher Umeå universitet, Klinisk kemi
publishDate 1993
url http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-101298
http://nbn-resolving.de/urn:isbn:91-7174-828-8
work_keys_str_mv AT slungalisbeth serumlipoproteinainrelationtoischemicheartdiseaseandassociatedriskfactors
_version_ 1716801694921129984